Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Cortesi

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
Cancer Treatment Reviews|October 22, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus projectStefania Gori, Fiorenza De Rose, Antonella Ferro, et al.
Cancers|January 30, 2020
The Spectrum of <i>FANCM</i> Protein Truncating Variants in European Breast Cancer CasesGisella Figlioli, Anders Kvist, Emma Tham, et al.
JCO Precision Oncology|September 14, 2019
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSarah M Nielsen, Diana M Eccles, Iris L Romero, et al.
Human Molecular Genetics|July 2, 2015
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorPaolo Peterlongo, Irene Catucci, Mara Colombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer RiskLenka Stolarova, Petra Kleiblova, Petra Zemankova, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk ScoresJulie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, et al.
Human Mutation|May 28, 2019
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classificationMichael T Parsons, Emma Tudini, Hongyan Li, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Cancer Treatment Reviews|October 22, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus projectStefania Gori, Fiorenza De Rose, Antonella Ferro, et al.
Cancers|January 30, 2020
The Spectrum of <i>FANCM</i> Protein Truncating Variants in European Breast Cancer CasesGisella Figlioli, Anders Kvist, Emma Tham, et al.
JCO Precision Oncology|September 14, 2019
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSarah M Nielsen, Diana M Eccles, Iris L Romero, et al.
Human Molecular Genetics|July 2, 2015
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorPaolo Peterlongo, Irene Catucci, Mara Colombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer RiskLenka Stolarova, Petra Kleiblova, Petra Zemankova, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Breast Cancer Research : BCR|February 10, 2016
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, et al.
Journal of the National Cancer Institute|July 28, 2021
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk ScoresDaniel R Barnes, Valentina Silvestri, Goska Leslie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk ScoresJulie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, et al.
Human Mutation|May 28, 2019
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classificationMichael T Parsons, Emma Tudini, Hongyan Li, et al.
Pageof 19